134 related articles for article (PubMed ID: 26293898)
1. The anti-ovarian cancer activity by WYE-132, a mTORC1/2 dual inhibitor.
Zhang D; Xia H; Zhang W; Fang B
Tumour Biol; 2016 Jan; 37(1):1327-36. PubMed ID: 26293898
[TBL] [Abstract][Full Text] [Related]
2. Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivo.
Pan XD; Gu DH; Mao JH; Zhu H; Chen X; Zheng B; Shan Y
PLoS One; 2017; 12(3):e0172555. PubMed ID: 28257457
[TBL] [Abstract][Full Text] [Related]
3. Autophagy inhibition sensitizes WYE-354-induced anti-colon cancer activity in vitro and in vivo.
Wang L; Zhu YR; Wang S; Zhao S
Tumour Biol; 2016 Sep; 37(9):11743-11752. PubMed ID: 27020593
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of WYE-687, a mTOR kinase inhibitor, as a potential anti-acute myeloid leukemia agent.
Cheng F; Wang L; Shen Y; Xia J; Chen H; Jiang Y; Lu M
Biochem Biophys Res Commun; 2016 Feb; 470(2):324-330. PubMed ID: 26792718
[TBL] [Abstract][Full Text] [Related]
5. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
Yu K; Shi C; Toral-Barza L; Lucas J; Shor B; Kim JE; Zhang WG; Mahoney R; Gaydos C; Tardio L; Kim SK; Conant R; Curran K; Kaplan J; Verheijen J; Ayral-Kaloustian S; Mansour TS; Abraham RT; Zask A; Gibbons JJ
Cancer Res; 2010 Jan; 70(2):621-31. PubMed ID: 20068177
[TBL] [Abstract][Full Text] [Related]
6. Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma.
Zheng B; Mao JH; Qian L; Zhu H; Gu DH; Pan XD; Yi F; Ji DM
Cancer Lett; 2015 Feb; 357(2):468-75. PubMed ID: 25444920
[TBL] [Abstract][Full Text] [Related]
7. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
[TBL] [Abstract][Full Text] [Related]
8. C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor.
Liu M; Gu P; Guo W; Fan X
Tumour Biol; 2016 Aug; 37(8):11039-48. PubMed ID: 26897748
[TBL] [Abstract][Full Text] [Related]
9. Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo.
Jiang SJ; Wang S
Tumour Biol; 2015 Sep; 36(10):8177-84. PubMed ID: 25990456
[TBL] [Abstract][Full Text] [Related]
10. Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014.
Huo HZ; Zhou ZY; Wang B; Qin J; Liu WY; Gu Y
Biochem Biophys Res Commun; 2014 Jan; 443(2):406-12. PubMed ID: 24309100
[TBL] [Abstract][Full Text] [Related]
11. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
Yu K; Toral-Barza L; Shi C; Zhang WG; Lucas J; Shor B; Kim J; Verheijen J; Curran K; Malwitz DJ; Cole DC; Ellingboe J; Ayral-Kaloustian S; Mansour TS; Gibbons JJ; Abraham RT; Nowak P; Zask A
Cancer Res; 2009 Aug; 69(15):6232-40. PubMed ID: 19584280
[TBL] [Abstract][Full Text] [Related]
12. The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1α and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways.
Kim BR; Yoon K; Byun HJ; Seo SH; Lee SH; Rho SB
Oncotarget; 2014 Aug; 5(15):6540-51. PubMed ID: 25153728
[TBL] [Abstract][Full Text] [Related]
13. Targeting sphingosine kinase 1/2 by a novel dual inhibitor SKI-349 suppresses non-small cell lung cancer cell growth.
Xue Y; Jiang K; Ou L; Shen M; Yang Y; Lu J; Xu W
Cell Death Dis; 2022 Jul; 13(7):602. PubMed ID: 35831279
[TBL] [Abstract][Full Text] [Related]
14. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
15. AT7867 Inhibits Human Colorectal Cancer Cells via AKT-Dependent and AKT-Independent Mechanisms.
Zhang S; Deng Z; Yao C; Huang P; Zhang Y; Cao S; Li X
PLoS One; 2017; 12(1):e0169585. PubMed ID: 28081222
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells.
Teo T; Yu M; Yang Y; Gillam T; Lam F; Sykes MJ; Wang S
Cancer Lett; 2015 Feb; 357(2):612-23. PubMed ID: 25527453
[TBL] [Abstract][Full Text] [Related]
18. mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo.
Zhang Y; Xu S; Lin J; Yao G; Han Z; Liang B; Zou Z; Chen Z; Song Q; Dai Y; Gao T; Liu A; Bai X
Breast Cancer Res Treat; 2012 Nov; 136(2):379-88. PubMed ID: 23053656
[TBL] [Abstract][Full Text] [Related]
19. The anti-esophageal cancer cell activity by a novel tyrosine/phosphoinositide kinase inhibitor PP121.
Peng Y; Zhou Y; Cheng L; Hu D; Zhou X; Wang Z; Xie C; Zhou F
Biochem Biophys Res Commun; 2015 Sep; 465(1):137-44. PubMed ID: 26235881
[TBL] [Abstract][Full Text] [Related]
20. Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells.
Wagner R; Stübiger G; Veigel D; Wuczkowski M; Lanzerstorfer P; Weghuber J; Karteris E; Nowikovsky K; Wilfinger-Lutz N; Singer CF; Colomer R; Benhamú B; López-Rodríguez ML; Valent P; Grunt TW
Oncotarget; 2017 Feb; 8(7):11600-11613. PubMed ID: 28086243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]